Work

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.4505

Authors: Daniel C. Cho, Jeffrey Alan Sosman, Mario Sznol, Michael S. Gordon, Antoine Hollebecque, Omid Hamid, David F. McDermott, Jean-Pierre Delord, Ina Park Rhee, Ahmad Mokatrin, Marcin Kowanetz, Roel Peter Funke, Gregg Daniel Fine, Thomas Powles

Institutions: Beth Israel Deaconess Medical Center, Vanderbilt University Medical Center, Yale University, Pinnacle Oncology Hematology, Institut Gustave Roussy, Angeles Clinic and Research Institute, Dana-Farber Cancer Institute, Institut Claudius Regaud, Genentech, Queen Mary University of London, Barts Health NHS Trust, Barts Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1904205116

Cites:

Cited by: 97

Related to: 10